Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Opko Health Q3 2026 Results: Net Loss of $53.5M

OPKO Health reported total assets of $1.88 billion as of September 30, 2026, with a significant shift of $248 million into current assets held for sale. The company maintains a cash position of $390.2 million while managing $370.2 million in senior secured royalty financing and $92.5 million in convertible notes.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue65.456.4
Profit before tax-37.9-41.0
Net income-53.521.6
EPS (diluted, $ a share)$-0.07$0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+15.9%
Operating margin-48.0%
Source

10-Q filed with the SEC, NASDAQ: OPK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Opko Health, Inc.: key numbers

Share price
$1.62Close, Nov 17
Market cap
$1.2B
Shares outstanding
742.51MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Opko Health, Inc.

All →
4:07 PM ET Form 4
Insider Selling

Opko Health Director John A. Paganelli Sells $16.7K of Stock

John A. Paganelli, Director, sold 9,175 shares of Opko Health, Inc. at $1.82 a share, worth $16.7K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).

Value
$16.7K
Shares
9,175
Price
$1.82
Role
Director
Holding change
-100.0%
Trade date
Nov 5, 2026
4:24 PM ET 8-K
Financial Results

Opko Health Financial Results

OPKO Health reported its third quarter 2026 financial results, highlighting a pending $722 million sale of its BioReference diagnostic operations to Labcorp. The company also expanded its financing with HealthCare Royalty by $125 million and advanced several clinical programs, including dosing the first participant in a Phase 1/2a trial for acromegaly.

Term
Q3 2026
4:08 PM ET 8-K
Divestiture

Opko Health Divestiture to Laboratory Corporation of America Holdings for $722M

OPKO Health and its subsidiary BioReference Health entered into a definitive agreement to sell certain assets of their clinical and anatomic pathology laboratory testing business to Labcorp for $722 million in cash. The deal includes clinical and women’s health testing, urology, and the proprietary 4Kscore prostate cancer test, with OPKO eligible for up to an additional $150 million in milestone payments over ten years based on 4Kscore revenue. The transaction is subject to HSR Clearance and customary closing conditions, with a target completion date by April 14, 2027.

Value
$722M
Counterparty
Laboratory Corporation of America Holdings
Term
up to 10 years
4:13 PM ET 8-K
Loan & Debt

Opko Health $121M Debt Financing with U.S. Bank Trust Company, National Association

OPKO Health announced that its 3.75% Convertible Senior Notes due 2029 have become convertible by holders through December 31, 2026, after the stock price exceeded 130% of the conversion price for a specified period. The company has elected to settle these conversion obligations in shares of common stock rather than cash. Approximately $121 million in principal amount of these notes remains outstanding.

Value
$121M
Counterparty
U.S. Bank Trust Company, National Association

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.